Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-...
Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. "I think that Stepha...
Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAd...
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefin...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 33.78% on an annualized basis producing an average annual return of 46.6...
Moderna Inc (NASDAQ:MRNA) shares are rising Monday after the company provided updates at a JPMorgan conference. What Happened: Moderna announced a ...
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and affo...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...